Carotid intima - Media Thickness (cIMT): A useful clinic tool or research luxury? Another view of the ENHANCE trial

Angiology

Volumn 59, Issue 2_suppl, 2008, Pages 77S-79S

  Toutouzas, P ^a   Richter, D ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b Athens Euroclinic   (Greece)

Author keywords

carotid intima media thickness; ENHANCE; ezetimibe

Indexed keywords

ESTRADIOL; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; AZETIDINE DERIVATIVE; EZETIMIBE SIMVASTATIN COMBINATION; EZETIMIBE-SIMVASTATIN COMBINATION; HYPOCHOLESTEROLEMIC AGENT; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ARTERIAL WALL THICKNESS; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL (TOPIC); FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; INTRAVASCULAR ULTRASOUND; RISK FACTOR; TREATMENT OUTCOME; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CLINICAL TRIAL; DRUG COMBINATION; INTIMA; OUTCOME ASSESSMENT; PATHOLOGY; REPRODUCIBILITY; REVIEW; TUNICA MEDIA;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SIMVASTATIN; TUNICA INTIMA; TUNICA MEDIA;

EID: 53049088814     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319708321748     Document Type: Conference Paper

References (11)

1. Simon A., Chironi G., Levenson J. Comparative performance of sublinical atherosclerosis tests n predicting coronary heart disease in asymptomatic individuals. Eur Heart J. 2007; 28: 2967-2971.
2. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. Ann Intern Med. 2001; 135: 939-953.
3. Smilde TJ, Van Wissen S., Wollersheim H., Trip MD, Kastelein JJ, Stalenhoef AF Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001; 357: 577-581.
4. Van Wissen S., Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol. 2005; 95: 264-266.
5. Kastelein JJ, Sager PT, de Groot E., Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J. 2005; 149: 234-239.
6. Kastelein JP, Akdim F., Stroes E., et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358: 1431-1443.
7. Lipid Research Clinics Program. JAMA. 1984; 252: 2545-2548.
8. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986; 8: 1245-1255.
9. Buchwald H., Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990; 323: 946-955.
10. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. The METEOR Trial. JAMA. 2007; 297: 1344-1353.
11. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trail comparing the effect of atrovastatin and pravastatin on carotid intima medial thickness. Circulation. 2002; 106: 2055-2060.